Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Vaxcyte (PCVX) Equity Average (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Equity Average data on record, last reported at $2.8 billion in Q1 2026.

  • On a quarterly basis, Equity Average fell 12.67% to $2.8 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $2.8 billion, a 12.67% decrease, with the full-year FY2025 number at $3.0 billion, up 31.79% from a year prior.
  • Equity Average reached $2.8 billion in Q1 2026 per PCVX's latest filing, up from $2.8 billion in the prior quarter.
  • Over the last five years, Equity Average for PCVX hit a ceiling of $3.4 billion in Q4 2024 and a floor of $321.8 million in Q1 2022.
  • A 5-year average of $1.8 billion and a median of $1.6 billion in 2024 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: skyrocketed 290.75% in 2023, then dropped 17.03% in 2025.
  • Tracing PCVX's Equity Average over 5 years: stood at $656.5 million in 2022, then soared by 101.32% to $1.3 billion in 2023, then surged by 154.37% to $3.4 billion in 2024, then decreased by 17.03% to $2.8 billion in 2025, then rose by 1.85% to $2.8 billion in 2026.
  • Business Quant data shows Equity Average for PCVX at $2.8 billion in Q1 2026, $2.8 billion in Q4 2025, and $3.0 billion in Q3 2025.